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MAP kinases act as an integration point for multiple biochemical signals and
are involved in a wide variety of cellular processes such as proliferation,
differentiation, regulation of transcription and development. As a member of
the MAP kinase family, ERK5 (MAPK7) is involved in the downstream
signalling pathways of various cell-surface receptors, including receptor tyrosine
kinases and G protein-coupled receptors. In the current study, five structures of
the ERK5 kinase domain co-crystallized with ERK5 inhibitors are reported.
Interestingly, three of the compounds bind at a novel allosteric binding site in
ERK5, while the other two bind at the typical ATP-binding site. Binding of
inhibitors at the allosteric site is accompanied by displacement of the P-loop into
the ATP-binding site and is shown to be ATP-competitive in an enzymatic assay
of ERK5 kinase activity. Kinase selectivity data show that the most potent
allosteric inhibitor exhibits superior kinase selectivity compared with the two
inhibitors that bind at the canonical ATP-binding site. An analysis of these
structures and comparison with both a previously published ERK5–inhibitor
complex structure (PDB entry 4b99) and the structures of three other kinases
(CDK2, ITK and MEK) in complex with allosteric inhibitors are presented.
1. Introduction
Mitogen-activated protein kinase (MAPK) signalling path-
ways are highly evolutionarily conserved throughout eukar-
yotes and perform key roles in mediating intracellular signal
transduction. Of the four mammalian MAP kinases, ERK
(extracellular signal-regulated kinase) 1/2, JNK, p38 and
ERK5 (MAPK7) (Raman et al., 2007; Chang & Karin, 2001;
Pearson et al., 2001), ERK5 is the most structurally divergent
of the family and is relatively poorly understood. The ERK5
protein, which is encoded by the MAPK7 gene (Zhou et al.,
1995), comprises an N-terminal kinase domain and a large
C-terminal domain containing transcriptional transactivating
functionality and nuclear localization and export sequences
(NLS/NES). ERK5 is the effector kinase of a canonical kinase
module comprising MEK (MAPK/ERK kinase) 5, MEKK
(MEK kinase) 2/3 and ERK5 itself (Lee et al., 1995).
Under normal physiological conditions, MEK5 and ERK5
are activated by growth factors and cellular stresses (Abe et
al., 1996; Kamakura et al., 1999) and, through the use of
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embryonic gene knockouts of MEK5 or MAPK7, have been
shown to contribute largely to blood-vessel and cardiac
formation during development (Wang et al., 2005; Regan et al.,
2002). In vitromuscle-differentiation systems have highlighted
prominent roles for ERK5 signalling in muscle development
(Dinev et al., 2001), whilst in adult tissues the pathway plays a
role in regulating the proliferation and survival of endothelial
cells and various immune-derived cell populations (Hayashi et
al., 2004; Sohn et al., 2008; Rovida et al., 2008; Garaude et al.,
2006).
In the context of cancer, clinical evidence suggests a role for
dysregulated MEK5/ERK5 signalling as a driver of tumour-
igenesis in several disease settings. Specifically, in breast
cancer, increased ERK5 protein levels are associated with
decreased disease-free survival. Furthermore, MEK5 expres-
sion is up-regulated by constitutive activation of STAT3
(signal transducer and activator of transcription 3), which is
commonly detected in advanced breast cancer (Song et al.,
2004; Montero et al., 2009). The ERK5 pathway also appears
to play a role in mediating chemoresistance and contributes to
neuregulin signalling in breast-cancer cells overexpressing
ErbB2 (Weldon et al., 2002; Esparı´s-Ogando et al., 2002). In
prostate cancer, MEK5 is overexpressed and is associated with
bone metastases, invasive potential and corresponding poor
survival (Mehta et al., 2003). Moreover, in hepatocellular
carcinoma (HCC), genetic dysregulation of MAPK7 expres-
sion through amplification of 17p11 is detectable in around
50% of primary HCC tumours (Zen et al., 2009). In the same
study, preclinical validation work using small interfering RNA
(siRNA) suppression of MAPK7 expression in amplified cell
lines confirmed a role for dysregulated MAPK7 in controlling
mitotic entry. Finally, recent findings from our own labora-
tories have implicated amplification of MAPK7 as a potential
tumour driver in sporadic cases of oesophageal and lung
squamous-cell carcinoma (Gavine et al., 2015).
Therapeutic intervention through the inhibition of ERK5
kinase activity may thus have utility in oncology, and a small-
molecule inhibitor of ERK5 with anti-proliferative effects in
both in vitro and in vivo models of cancer has been reported
(Yang et al., 2010). Several compounds showing ERK5 inhi-
bition in biochemical and cell-based assays have also been
described (Tatake et al., 2008; Deng et al., 2013). In the work
presented here, we describe several novel small-molecule
ERK5 inhibitors which were identified as part of a high-
throughput screen of our corporate collection. Interestingly,
co-crystal structures of these inhibitors with the kinase domain
of ERK5 showed that one class of these ERK5 inhibitors
comprises novel allosteric kinase inhibitors that bind at an
induced-fit pocket adjacent to the ATP-binding site formed as
a result of remodelling of the P-loop. The other class, mean-
while, binds at the conventional ATP-
binding site. The most potent allosteric
inhibitor demonstrates a half-maximal
inhibitory concentration (IC50) of
2.3 mM in our enzymatic assay, and its
ERK5 inhibition is ATP-competitive.
The co-crystal structures of our novel
allosteric inhibitors are described and
compared with those of conventional
ERK5 inhibitors and with known allo-
steric inhibitors of cyclin-dependent
kinase 2 (CDK2), MAPK kinase (MEK)
and interleukin 2-inducible T-cell kinase
(ITK).
2. Experimental procedures
2.1. Cloning, expression and
purification
Human ERK5 (amino acids 46–402)
was amplified from synthetic DNA (Life
Technologies) and fused to a DNA
sequence coding for glutathione S-
transferase (GST) and a Tobacco etch
virus (TEV) protease cleavage site
(sequence details are provided in the
Supporting Information). The resulting
construct was cloned into the vector
pFastBac HT A using standard
molecular-biology protocols, and
recombinant baculovirus was produced
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Figure 1
Chemical structures of the ERK5 inhibitors used in this study.
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following the instructions given by the supplier. The protein
was expressed in Sf9 insect cells grown in single-use WAVE
bioreactors using a titreless infection protocol at 299 K for
64 h. The cells were harvested by centrifugation, washed with
1 phosphate-buffered saline (PBS) and stored at 193 K until
purification.
For purification, frozen cells were thawed in 1 PBS
supplemented with 10% glycerol, 5 mM dithiothreitol (DTT),
cOmplete Protease Inhibitor Cocktail (Roche) and DNase,
and were lysed with an Ultra-Turrax. After centrifugation (all
purification steps were performed at 277 K), the supernatant
was applied onto a 20 ml column of glutathione (GSH)
Sepharose (GE Healthcare) and the bound protein was eluted
with 10 mM reduced GSH. The fusion tag was removed by
digestion with recombinant TEV protease overnight whilst
dialysing against approximately 100 volumes of buffer without
glutathione. Cleaved ERK5 protein was further purified by a
second passage over the GSH Sepharose column followed
by size-exclusion chromatography on a Superdex 75 26/60
column (GE Healthcare) equilibrated in 20 mM Tris–HCl
pH 8.0, 250 mM NaCl, 10% glycerol, 2 mM DTT. ERK5-
containing fractions were diluted fivefold with 50 mM HEPES
pH 6.5, 10% glycerol, 2 mM DTT and applied onto a 6 ml
Resource S column equilibrated in the same buffer. Protein
bound to the column was eluted with a gradient to 200 mM
NaCl, and ERK5-containing fractions were pooled and
concentrated to >12 mg ml1 as determined by a standard
Bradford assay.
2.2. Crystallization and data collection
The structure of ERK5 in complex with compound 2 (Fig. 1)
was obtained by soaking the compound at a final concentra-
tion of 5 mM and 5%(v/v) DMSO into pre-formed apo crystals
[grown from 13%(w/v) PEG 4000, 180 mM sodium formate,
100 mMMES pH 6.5, 10 mM Tris–HCl pH 8.5, 10 mMMgCl2]
for 30 min at 277 K.
The structures of ERK5 in complex with compounds 3, 4, 5
and 6 were obtained by co-crystallization. Purified recombi-
nant human ERK5 kinase domain in storage buffer [50 mM
HEPES pH 6.5, 120 mMNaCl, 10%(v/v) glycerol, 2 mMDTT]
was incubated for 3 h on ice with compound diluted from
either a 100 mM stock in DMSO to a final concentration of
1 mM compound, 1%(v/v) DMSO, 12 mg ml1 protein
(compounds 3 and 4; Fig. 1) or diluted from a 20 mM stock in
2,3-butanediol to a final concentration of 0.2 mM compound,
1%(v/v) 2,3-butanediol, 12 mg ml1 protein (compounds 5
and 6; Fig. 1). Samples were then clarified by centrifugation
(5 min, 13 000g, 277 K). Crystals with compound 3 were grown
by hanging-drop vapour diffusion at 277 K by mixing the
protein–compound complex with mother liquor [11%(w/v)
PEG 4000, 180 mM sodium formate, 100 mM MES pH 6.5,
research papers
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Table 1
Crystallographic statistics.
Values in parentheses are for the outer resolution shell.
Compound 2 3 4 5 6
PDB code 5byy 5byz 4zsg 4zsj 4zsl
Beamline X06SA, SLS X06SA, SLS ID23.1, ESRF I02, DLS MX2, AS
Wavelength (A˚) 1.00003 1.00003 0.972 0.979 0.950
Detector Pilatus 6M Pilatus 6M ADSC Q315 CCD ADSC Q315 CCD ADSC Q315 CCD
Data-collection date 11/06/2012 10/05/2012 22/11/2012 11/07/2013 29/08/2013
Space group P41212 P41212 P41212 P41212 P41212
Unit-cell parameters
a = b (A˚) 92.79 93.40 92.53 93.04 92.69
c (A˚) 107.30 116.28 107.48 110.61 111.04
Resolution range (A˚) 70.19–2.79 (3.04–2.79) 72.82–1.65 (1.74–1.65) 50.0–1.79 (1.85–1.79) 71.2–2.48 (2.54–2.48) 47.63–2.25 (2.32–2.25)
Completeness (%) 99.9 (100) 99.5 (99.8) 99.4 (98.7) 99.9 (99.8) 99.8 (98.1)
Unique reflections 12125 62054 44410 17842 23699
Multiplicity 5.9 (5.7) 7.1 (7.0) 10.6 (10.8) 10.8 (11.3) 7.9 (7.7)
Mean I/(I) 21.7 (4.0) 24.2 (3.3) 20.9 (1.7) 19.1 (3.5) 17.5 (1.9)
Rmerge† 0.069 (0.440) 0.046 (0.690) 0.055 (1.257) 0.110 (0.719) 0.089 (1.203)
R value‡ (%) 22.3 17.4 20.6 17.0 17.7
Rfree§ (%) 27.3 19.2 23.5 23.0 21.9
Non-H protein atoms 2739 2960 2794 2794 2737
Non-H ligand atoms 35 34 20 21 25
Solvent molecules 17 337 344 261 276
R.m.s. deviations from ideal values
Bond lengths (A˚) 0.008 0.009 0.010 0.010 0.010
Bond angles () 1.07 1.20 1.02 1.06 1.00
Average B value for protein (A˚2) 23.3 21.7 55.2 47.9 46.6
Average B value for ligand (A˚2) 62.0 23.9 39.2 68.2 73.7
Average B value for water (A˚2) 14.5 30.3 57.6 56.6 56.4
’,  angle distribution for residues}
In favoured regions (%) 95 95.7 94.3 95.3 95.9
In allowed regions (%) 4.2 3.6 4.8 4.1 3.8
In outlier regions (%) 0.8 0.7 0.9 0.6 0.3
† Rmerge =
P
hkl
P
i jIiðhklÞ  hIðhklÞij=
P
hkl
P
i IiðhklÞ. ‡ R =
P
hkl

jFobsj  jFcalcj

=
P
hkl jFobsj. § Rfree is the cross-validation R factor computed for a test set consisting of 5% of the
unique reflections. } Ramachandran statistics as defined by Coot.
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10 mM Tris–HCl pH 8.5, 10 mM MgCl2] in a 0.75:0.5 ratio to
give a 2.0 ml drop. Crystals of ERK5 with compounds 4, 5 and
6 were grown by hanging-drop vapour diffusion at 293 K from
a mother liquor consisting of 4–6%(w/v) PEG 6000, 100 mM
MES pH 6.25, 5 mM DTT using a 1:1 drop ratio and a final
drop size of 0.7–1.0 ml. Drops were immediately streak-seeded
using a seed stock supplied by Proteros biostructures GmbH.
Crystals appeared within 4 d and were harvested after 6 d into
a cryoprotectant solution consisting of 70%(v/v) mother
liquor, 30%(v/v) glycerol. After around 10 s of equilibration,
crystals were flash-cooled in a stream of gaseous nitrogen at
100 K.
X-ray diffraction data were collected at the Swiss Light
Source (SLS), the European Synchrotron Radiation Facility
(ESRF), Diamond Light Source (DLS) and the Australian
Synchrotron (AS) (McPhillips et al., 2002; see Table 1 for
details). Data were integrated, scaled and merged using XDS
(Kabsch, 2010) and AIMLESS (Winn et al., 2011; Evans &
Murshudov, 2013). Structures were solved, initial refinement
was carried out and the ligand was fitted to difference electron
density using the programs Phaser (McCoy et al., 2007),
BUSTER (Bricogne et al., 2011) and rhofit (Womack et al.,
2010) as implemented in the automated structure-solution
pipeline Pipedream (Sharff et al., 2011). A high-resolution
structure of the ERK5 kinase domain supplied by Proteros
biostructures GmbH was used as the search model for mole-
cular replacement. Coordinates and stereochemical restraints
for compounds were generated from the appropriate SMILES
strings using grade (Smart et al., 2011). Manual model
completion was carried out using Coot (Emsley et al., 2010),
interspersed with rounds of refinement in BUSTER (Bricogne
et al., 2011). The quality of the final model was verified using
MolProbity (Chen et al., 2010), PROCHECK (Laskowski et
al., 1993), Mogul (Bruno et al., 2004) and the validation tools
available through Coot (Emsley et al., 2010). Full statistics of
the data collection, refinement and final model quality are
provided in Table 1. Coordinates, structure factors and full
experimental conditions have been deposited with the Protein
Data Bank (PDB) under accession codes 5byy, 5byz, 4zsg, 4zsj,
and 4zsl for the structures of the complexes of ERK5 with 2, 3,
4, 5 and 6, respectively. CCP4mg (McNicholas et al., 2011)
was used for structure alignment and figure preparation.
Simulated-annealing OMIT maps were calculated using
phenix.refine (Afonine et al., 2012).
2.3. Biochemical assay for ERK5 IC50 determination
Catalytically active kinase domain of recombinant human
ERK5 enzyme was purchased from Carna Biosciences. The
crystallography-grade protein described in x2.1 is not phos-
phorylated and thus is inactive and unsuitable for use in the
enzymatic assay. The inhibitory potency of compounds against
ERK5 was evaluated using the LANCEUltra technology from
PerkinElmer according to the manufacturer’s instructions.
Briefly, 3 ml of different concentrations of ATP and 100 nM
ULight-eIF4E-binding protein 1 (Thr37/46) peptide (Perkin-
Elmer catalogue No. TRF0128) were incubated in the
presence of serially diluted compound or DMSO control at
room temperature in 384-well Greiner white polystyrene assay
plates. The reaction was initiated by the addition of 3 ml of
10 nM kinase. The assay buffer consisted of 1 mM DTT,
10 mM MgCl2, 1 mM EGTA, 0.01%(v/v) Tween 20 in 50 mM
HEPES pH 7.5. After 60 min incubation, the reaction was
stopped by the addition of 6 ml stop/detection reagent mixture
consisting of 20 mM EDTA and 4 nM Eu-anti-phospho-
eIF4E-binding protein 1 (Thr37/46) antibody (PerkinElmer
catalogue No. TRF0216) diluted in detection buffer. The
plates were incubated for 1 h before the fluorescence was
measured at 615 and 665 nm with an excitation wavelength of
320 nm using an EnVision Multilabel Reader from Perkin-
Elmer in time-resolved fluorescence resonance energy
transfer (TR-FRET) mode. The calculated signal ratio at 665/
615 nm is proportional to the kinase activity. The concentra-
tion of compound producing 50% inhibition of the kinase
activity (IC50) was calculated by using GraphPad Prism to fit
the data to a symmetrical sigmoidal curve.
2.4. Kinase-panel activity screen
Compounds 2, 3 and 5 were tested for activity against the
225 kinases in the ThermoFisher standard kinase panel. The
standard Z0-LYTE assay protocol (ThermoFisher) was used
to measure the percentage inhibition at 10 mM compound
concentration (details are provided in the supporting infor-
mation).
3. Results and discussion
3.1. Identification of novel ERK5 inhibitors
The previously reported ERK5 inhibitor XMD8-92
(compound 2; Fig. 1; Yang et al., 2010) was used as a reference
compound in the development and validation of a TR-FRET-
based biochemical assay of ERK5 kinase activity (Table 2).
The crystal structure of compound 1 (Fig. 1), a close analogue
of compound 2, in complex with ERK5 (PDB entry 4b99) has
recently been published (Elkins et al., 2013). The IC50 value
measured for compound 2 against ERK5 in our assay is in
good agreement with that reported in the literature for
compound 1 (Table 2; Deng et al., 2013). Our previous results
also demonstrated that compound 2, as an ERK5 tool
compound, was able to block downstream ERK5 signalling
in a HEK293 cell line which stably co-expressed both a
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Table 2
Enzymatic potency data for ERK5 inhibitors.
Compound ERK5 IC50 (mM)
1 0.082†
2‡ 0.098
3 0.042
4 >10
5 2.3
6 >10
† Data retrieved from the literature (Deng et al., 2013). ‡ XMD8-92 in the literature
(Yang et al., 2010).
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constitutively active variant of MEK5 (MEK5CA) and ERK5
(Gavine et al., 2015). Compounds 3–6 were identified as
potential novel ERK5 inhibitors originating from a high-
throughput screen of the AstraZeneca corporate collection
using the TR-FRET assay. Compounds 4–6 are close analo-
gues of one another. It is worthwhile pointing out that the
biochemical assay that we employed to measure ERK5
activity uses phosphorylated ERK5 and thus provides a
measure of binding to the phosphorylated state via inhibition
of activity, while the ERK5 crystal system that we employed
uses nonphosphorylated ERK5 protein and thus provides a
readout of binding to the nonphosphorylated state.
3.2. Overall structures of ERK5–inhibitor complexes
The structures of the ERK5 kinase domain in complex with
compounds 2–6 were solved by molecular replacement to
resolutions ranging from 1.65 to 2.79 A˚ (Table 1) and contain
one molecule of ERK5 in the crystallographic asymmetric
unit, which displays the characteristic two-lobe kinase domain
structure. Key features of the ERK5 kinase domain are indi-
cated in Fig. 2, including the hinge region (Leu137–Glu141)
which links the two lobes, the glycine-rich P-loop (Ile61–
Val69) that encloses the ATP-binding site, the C helix and
the activation loop, which is bounded by the conserved DFG
(Asp200–Gly202) and APE (Ala229–Glu231) motifs. The
ERK5 C-terminus extends beyond the canonical kinase
domain, forming an extended loop followed by an -helix,
which pack against the N-terminal lobe, stabilizing the C
helix in an active-like conformation. Residues Asp53–Arg392
have been modelled in the structures of the complexes with
compounds 3–6. Residues 208–215, corresponding to the
central portion of the activation loop, could not be modelled
in the complex with compound 2. In a subset of the structures,
sufficient electron density was visible at the N- and C-termini
to allow up to four additional residues to be modelled. Outside
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Figure 2
Structure of ERK5 in complex with XMD8-92 (compound 2). ERK5 is
shown in ribbon representation with the hinge region, P-loop, C helix
and activation loop coloured yellow, blue, coral and magenta,
respectively. The central portion of the activation loop (amino acids
208–215) is missing from the model. XMD8-92 (compound 2) binds in the
ATP-binding site and is shown as a stick model with C atoms in green.
The 2mFo  DFc OMIT electron density for compound 2 is shown as a
lilac mesh contoured at 1.0.
Figure 3
Comparison of the co-crystal structures of ERK5 in complex with the
conventional ATP-binding site inhibitors 1 (PDB entry 4b99), 2 and 3
with those of ERK5 in complex with the allosteric inhibitors 4, 5 and 6.
Displacement of the P-loop into the ATP-binding site upon binding of 4, 5
and 6 is highlighted. The protein backbone for the complex of ERK5 with
compounds 1 (coloured by secondary-structural element with -sheets,
-helices and loops in sea green, pale crimson and grey, respectively) and
4 (coral) is shown as a worm representation. Bound ligands are rendered
as sticks with C atoms coloured pink (compound 1), green (compound 2),
grey (compound 3), coral (compound 4), cyan (compound 5) and
magenta (compound 6). The side chains of the gatekeeper residue
(Leu137) and the DFG motif (Asp200 and Phe201) from the complex of
ERK5 with compound 1 are shown as sticks with C atoms in grey. In (b),
the view has been rotated 90 with respect to (a), such that the viewer
looks onto the kinase N-lobe, and the C-lobe has been omitted for clarity.
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the P-loop, all five structures are very similar, exhibiting an
overall root-mean-square deviation (r.m.s.d.) of 0.52–0.78 A˚
over 323–334 C coordinates.
An overlay of the co-crystal structures of ERK5 in complex
with the inhibitors 2–6 on the published co-crystal structure
with compound 1 (PDB entry 4b99) is shown in Fig. 3. Inter-
estingly, these inhibitors occupy two different binding sites on
ERK5. Compounds 2 and 3, like compound 1, bind at the
conventional ATP-binding site, while compounds 4, 5 and 6
bind at a novel allosteric binding site. The allosteric binding
site is located in a cleft between the P-loop and the C helix
adjacent to the ATP-binding site. This type of allosteric
binding site has been reported for other kinases (Chaikuad et
al., 2014; Han et al., 2014; Ohren et al., 2004; Martin et al.,
2012); however, this is the first time it has been described in
ERK5. Among these three allosteric inhibitors, 5 is the most
potent, with an IC50 of 2.3 mM in the biochemical assay
(Table 2).
It can be seen from Fig. 3 that, as a consequence of forming
the allosteric binding site, the P-loop is pushed away from the
C helix to block the ATP-binding site, thus suggesting that
these allosteric inhibitors should be ATP-competitive. An
ATP-competition study was therefore carried out to verify this
hypothesis. A comparison of the IC50 curves at different ATP
concentrations for the allosteric inhibitor 5 and the reference
compound 2 shows that with increasing ATP concentration the
IC50 values for both compounds 2 and 5 consistently increase
(Table 3 and Fig. 4). These results suggest that the ERK5
inhibition of compound 5, like that of compound 2, is indeed
ATP-competitive.
3.3. Binding modes of compounds 2 and 3, two conventional
ERK5 inhibitors
Unsurprisingly, given the similarity of the two compounds,
the structure of ERK5 in complex with compound 2 is similar
to that of ERK5 in complex with compound 1 (PDB entry
4b99; Fig. 5a). Compound 2 has a primary alcohol in place of
the methylpiperazine group of compound 1, an N-methyl in
place of the N-cyclopentyl substituent on the tricyclic ring
system, and an O-ethyl in place of an O-methyl at the meta-
position of the phenyl group. These changes combine to yield
a compound with a similar inhibitory potency to compound 1
(Table 2).
As observed for the reference compounds 1 and 2,
compound 3 binds at the conventional ATP-binding site
(Figs. 3, 5b and 5c). The aminopyrimidine motif forms a
hydrogen-bond network with the backbone of Met140 in the
ERK5 hinge region. The imidazole ring is located in the back
pocket (BP; Fig. 5c) of the ATP-binding site and one aromatic
N atom in the ring forms a hydrogen bond to the side-chain
amino group of Lys84. The amide substituent on the phenyl
ring of compound 3 extends into the solvent-accessible
channel (the so-called front pocket; FP) and the amide NH
donates a hydrogen bond to the side-chain amide carbonyl O
atom of Gln146. The terminal piperidine ring provides an
additional ionic interaction with the likely deprotonated
carboxylic acid of Asp143.
An overlay of the structures of ERK5 in complex with
compounds 1, 2 and 3 (Fig. 5c) shows that the aminopyr-
imidine ring of compound 3 penetrates deeper into the ERK5
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Table 3
The derived IC50 values at varying ATP concentrations.
[ATP] (mM)
IC50 (mM) 20 40 60 80 200 500 1000 2000
Compound 2 0.16 0.14 0.15 0.17 0.21 0.36 0.59 0.9
Compound 5 2.3 2.9 3.1 3.4 4.1 6.3 9.9 14.8
Figure 4
Influence of ATP concentration on IC50 curves for (a) compound 2 and
(b) compound 5.
electronic reprint
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Figure 5
(a) An overlay of the structures of ERK5 in complex with compound 1 (C atoms in pink) and compound 2 (C atoms in green) highlights their similarity in
binding mode. Hydrogen bonds between compound 2 and ERK5 are shown as black dashed lines. (b) Compound 3 binds to the ATP-binding site of
ERK5, making hydrogen-bond interactions with the hinge (Met140), solvent channel (Asp143 and Gln146) and catalytic lysine (Lys84). The 2mFoDFc
OMIT electron density for compound 3 is shown as a lilac mesh contoured at 1.5. Hydrogen bonds are shown as dashed black lines. ERK5 and
compound 3 are shown in stick representation with C atoms in grey. (c) Compounds 1, 2 and 3 show subtle differences in binding mode as a result of
differences in their substitutions, although they utilize a similar aminopyrimidine hinge-binding motif. ERK5 is rendered as sticks with C atoms in grey
(complex with compound 1). Compounds are rendered as sticks with C atoms in pink (compound 1), green (compound 2) or grey (compound 3). Leu137
(the gatekeeper residue), Leu139 in the hinge, the front pocket (FP) and the back pocket (BP) are labelled.
binding pocket than the equivalent hinge-binding motifs of
compounds 1 and 2. The tricyclic ring systems of compound 1,
and to a somewhat lesser extent compound 2, however, occupy
a greater volume than the equivalent region of compound 3,
with the benzene-ring fragment extending downwards to fit
into the base of the ATP-binding site, whilst in compound 1
the N-cyclopentyl substituent points upwards towards the
P-loop and packs against Ile61. The N-isopropyl group of
compound 3 is positioned similarly to the benzene ring in the
6,7,6 ring systems of compounds 1 and 2. In contrast to the
poorly defined conformation of the piperidine ring in
compound 3, the solvent-exposed piperidine–piperazine
moiety of compound 1 is directed out of the ATP-binding site
and is located adjacent to the P-loop.
3.4. Binding mode of allosteric ERK5 inhibitors
Compounds 4, 5 and 6 bind at a different binding site to
compounds 1, 2 and 3. This site lies adjacent to the ATP-
binding site (Figs. 3 and 6 and Supporting Information). The
para-chloro-substituted phenyl ring of 4 protrudes deeply into
a hydrophobic pocket which is formed by the side chains of
Ile86, Leu103, Ile117 and Val135 from the 3 strand, the C
helix and the 4 and 5 strands, respectively (Fig. 6a). An
intramolecular hydrogen bond between the amide O atom and
the aniline N atom forms a pseudo-bicyclic ring system that
maintains the compound in a planar conformation. The
primary amine donates hydrogen bonds to the side chains of
both Asn95 and Thr99 from the C helix. One face of the
pocket is defined by the side chains of Arg98 and Glu102 from
the C helix, which form a favourable salt bridge with one
another. – stacking is observed between the triazole ring
and the guanidinium group of Arg98. Formation of a hydrogen
bond between Glu102 and the hydroxyl group of Tyr66
from the tip of the P-loop stabilizes the P-loop in a closed
electronic reprint
conformation. The terminal isopropyl group of compound 4 is
largely solvent-exposed and yet is well defined in the electron
density (Fig. 6a and Supporting Information).
Compounds 5 and 6 are close analogues of compound 4, and
they adopt a similar binding mode (Figs. 6b, 6c and 6d and
Supporting Information). The meta methyl substituent on the
chlorophenyl ring of compound 5 is well accommodated in the
binding pocket, and is likely to contribute to the increased
potency measured for this inhibitor (Table 2). The 2-methyl-
phenyl substituent of compound 6, which replaces the
isopropyl group of compounds 4 and 5, is solvent-exposed and
does not appear to contribute any interactions, consistent with
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Figure 6
(a, c, d) Compounds 4 (C atoms in green) (a), 6 (C atoms in magenta) (c) and 5 (C atoms in cyan) (d) bind to a novel allosteric pocket situated between
the C helix (coral) and the P-loop (blue) of ERK5. Hydrogen bonds are shown as dashed black lines. ERK5 is rendered in ribbon representation and
coloured as in Fig. 2, with selected side chains, including those of the gatekeeper (Leu137) and the DFG motif (Asp200, Phe201 and Gly202), shown as
sticks. In (a) the 2mFo  DFc OMITelectron density for compound 4 is shown as a lilac mesh contoured at 1.0. (b) Compounds 4, 5 and 6 show similar
binding modes. ERK5 is shown in worm representation with selected side chains and bound compounds rendered as sticks with C atoms in green
(complex with compound 4), cyan (complex with compound 5) or magenta (complex with compound 6). (e) Sequence alignment for members of the
MAPK family, highlighting areas of conservation in the region of the allosteric binding pocket. Residues contacting compound 5 are indicated by filled
black triangles above the sequence. Key secondary-structural elements are shown below the sequence.
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the limited potency of compound 6 (Table 2) and the ambi-
guity of the electron density for this portion of the molecule
(Supplementary Fig. S2).
As observed for the complex of compound 1 with ERK5
(Yang et al., 2010), compounds 2–5 bind to a ‘DFG-in’
conformation of ERK5 in which both the hydrophobic
R-spine (residues Leu106, Ile117, His180 and Phe201 in
ERK5) and C-spine (Val69,
Ala82, Leu144, Leu188, Leu189,
Val190, Ile251 and Met255) are
intact. Compared with the struc-
tures of ERK5 in complex with
the hinge-binding compounds 1–
3, however, the P-loop is pushed
away from the C helix towards
the ATP-binding site upon allos-
teric inhibitor binding (Fig. 3;
compare the grey and coral P-
loops). Differential flexibility in
the P-loop amongst kinases has
been implicated in the selectivity
of certain conventional ATP-
binding site-targeted kinase inhi-
bitors (Guimara˜es et al., 2011), and may have implications for
the selectivity of our allosteric ERK5 inhibitors (see x3.5). In
contrast to the P-loop, the C helix orientation is unchanged
upon the binding of compounds 4–6 (Fig. 3). The position of
this helix is constrained in ERK5 by packing against the
adjacent C-terminal extension (Pro361–His389; Fig. 2).
Although the C helix remains in an active-like conformation,
the salt bridge between Lys84 (from strand 3) and Glu102
(from the C helix), which is characteristic of an active kinase,
is disrupted (Fig. 6a). The side chain of Lys84 is displaced by
binding of compounds 4–6 and reorients to form a hydrogen
bond to the backbone carbonyl of Val68 from the P-loop.
Glu102, meanwhile, adopts an alternative rotamer allowing
the formation of a salt bridge with Arg98 and a hydrogen bond
to Tyr66. This new network of hydrogen bonds contributes to
stabilization of the allosteric pocket. Conservation of the
ERK5 C helix conformation upon binding of compounds 4–6
further differentiates this inhibitor-binding mode from those
of other reported allosteric kinase inhibitors (see x3.6 and
Fig. 9).
3.5. Allosteric and conventional ERK5 inhibitors show
differing selectivity profiles
Compounds 2, 3 and 5 were tested against a panel of 225
kinases representative of the kinome to assess the selectivity
of these three different scaffolds. The kinase selectivity-profile
data (Fig. 7 and Supporting information) show that compound
5 is the most selective, while compound 3 is the most
promiscuous, with the selectivity of compound 2 being inter-
mediate. The selectivity of compound 1, and related
compounds such as compound 2, for ERK5 over other kinases
has been extensively discussed (Elkins et al., 2013).
Consideration of the key interactions made between
compound 5 and ERK5 explains the selectivity of this
compound for ERK5 over other members of the MAPK
family, and suggests that compounds 4 and 6 will show similar
selectivity (Fig. 6e). The side chain of Thr99 forms a hydrogen
bond to the amino group of compound 5 (Fig. 6a); this is one
of only two hydrogen bonds between ERK5 and this
compound. The residue equivalent to Thr99 is conserved as a
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Figure 7
Kinase-panel selectivity for ERK5 inhibitors 2, 3 and 5. The violet lines indicate kinases for which the
percentage inhibition is above 80%, the orange lines those where it is between 40 and 80%, and the light
blue lines those where it is less than 40%.
Figure 8
Chemical structures of representative allosteric inhibitors of MEK, ITK
and CDK2.
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threonine in ERK1, ERK2, p38 and p38, but is an alanine in
ERK3, ERK4, p38 and p38. A second nonconserved residue
in the allosteric binding site is Val135, which forms one face of
the pocket, and against which the phenyl moiety of the
allosteric binders packs. In ERK1–4, ERK7/8 and the p38
MAPKs, this residue is a bulkier isoleucine or leucine. Simi-
larly, Ile86, which also contributes to this face of the pocket,
although conserved across the ERK MAPKs, is a leucine in
the p38 MAPKs. The so-called gatekeeper residue Leu137 lies
within 3.5 A˚ of the methyl substituent on the phenyl ring of
compound 5. The identity of the gatekeeper exhibits consid-
erable variability amongst members of the MAPK family and
is a glutamine in ERK1, ERK2, ERK3 and ERK4, a threonine
in p38 and p38, a methionine in p38 and p38 and a
phenylalanine in ERK7/8, thus significantly altering the
properties of this part of the allosteric pocket. Three addi-
tional hydrophobic residues (Leu103, Leu106 and Ile117)
which contribute to the binding pocket for compound 5 show
variation across the MAPK family (Fig. 6e). Consistent with
the differences in amino-acid composition of the allosteric
binding pocket, compound 5 showed less than 10% inhibition
when tested against a panel of MAP kinases including ERK1,
ERK2 and p38 (Supporting Information).
Compound 5 shows greater than 80% inhibition against five
other kinases in the panel of 225: colony-stimulating factor 1
receptor (CSF1R) kinase, FLT4 [vascular endothelial growth
factor receptor (VEGFR) 3 kinase], glycogen synthase kinase
(GSK) 3, spleen tyrosine kinase (SYK) and nonreceptor
tyrosine protein kinase TYK2 (Fig. 7 and Supporting Infor-
mation). The reason for this cross-reactivity is not clear from
sequence alignments or the available structures for these five
kinases and may arise from an alternative binding mode in
which compound 5 binds at the ATP-binding site through a
canonical hinge-binding donor–acceptor–donor motif.
3.6. ERK5 allosteric inhibitors in the context of the kinome
Kinase inhibitors typically fall into two major classes
(Knight & Shokat, 2005): type I inhibitors that target a kinase
Figure 9
Comparison of the ERK5 allosteric ligand-binding mode with allosteric inhibitors of (a, b) MEK1/2 (PDB entries 1s9i and 1s9j; Ohren et al., 2004), (c)
ITK (PDB entry 4m0y; Han et al., 2014) and (d) CDK2 (PDB entry 3py1; Betzi et al., 2011) highlights the changes in C helix orientation and P-loop
conformation associated with inhibitor binding. In (a), (c) and (d) the structures are oriented such that the viewer looks onto the kinase C-lobe, and the
N-terminal -sheet has been omitted for clarity. In (b) the view has been rotated 90 with respect to (a) to show the differences in P-loop conformation.
Structures were superposed by matching residues corresponding to the -sheet and hinge region of the N-terminal lobe of ERK5 kinase (amino acids 55–
61, 70–88, 108–123 and 131–140). ERK5 (coloured as in Fig. 2), MEK (gold), ITK (cyan) and CDK2 (lilac) are shown in ribbon representation. Bound
ligands are rendered as sticks with C atoms coloured green (compound 4), pink (ATP), cyan (MEK inhibitor; compound 7), magenta (ITK inhibitor;
compound 8), purple (SU9516) and cyan (ANS; compound 9).
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active state and bind at the ATP-binding site (such as
compounds 1, 2 and 3) and type II inhibitors that target an
inactive form. The latter are usually characterized by a
‘flipped-out’ conformation of the activation-loop DFG
motif and extend beyond the ATP-binding site to additionally
occupy a hydrophobic pocket (Zhang et al., 2009). Selectivity
can be major challenge in both cases (Mu¨ller et al.,
2015). Allosteric inhibitors such as 4, 5 and 6 are much
rarer.
The most thoroughly characterized allosteric kinase inhi-
bitors are those targeting MEK1/2; for example, PD318088
(compound 7; Fig. 8), cobimetinib and selumetinib (Ohren et
al., 2004; Hatzivassiliou et al., 2013; Templeton &Musib, 2015).
These compounds bind in a similar region of the MEK kinase
as compounds 4, 5 and 6 in ERK5, and likewise bury a para-
halogen-substituted phenyl ring within a broadly equivalent
pocket (Figs. 9a and 9b and Supporting Information). Few
specific interactions are conserved, however, and most notably
the MEK inhibitors do not reorder the P-loop towards the
ATP-binding site (Fig. 9b) and are noncompetitive with ATP
(Fig. 9b). Indeed, the MEK inhibitors can directly interact
with the ATP-coordinated Mg2+ ion, forming a MEK–ATP–
Mg2+–inhibitor complex.
More recently, allosteric inhibitors of ITK (Han et al., 2014)
have been reported (compound 8; Fig. 8). Again, these inhi-
bitors bind in a similar region of the kinase fold; however, the
pocket is more deeply buried compared with the site identified
here for ERK5 (Fig. 9c and Supporting Information). The
specific interactions also differ markedly; in the ITK case a
buried network of hydrogen bonds is formed, coordinating
both a urea and an amide group within the allosteric pocket,
whilst a naphthyl group distorts the C helix. As for the MEK
allosteric inhibitors, the ITK allosteric inhibitors differ from
the ERK5 allosteric inhibitors presented here in that they are
noncompetitive with ATP.
A third example of allosteric inhibitors binding in this
region of the kinase fold is provided by a series of naphthalene
sulfonates binding to CDK2 (Martin et al., 2012; ANS;
compound 9; Fig. 8). The binding mode of these inhibitors
more closely resembles that of the ITK allosteric inhibitors
than the ERK5 ligands described here, with a sulfonate buried
analogously to the urea group (Fig. 9d and Supporting Infor-
mation). Uniquely in the case of CDK2, a second inhibitor
molecule binds at an adjacent allosteric site, displacing the C
helix such that the complex can no longer bind cyclin. Again,
these allosteric inhibitors of CDK2 are noncompetitive with
ATP.
In both the MEK and ITK allosteric inhibitor examples,
broad kinase activity screening has demonstrated that these
allosteric ligands are highly selective for their respective
targets. Compound 5, the most potent of the allosteric
ERK5 inhibitors identified in this study, also shows a high
level of selectivity over other kinases (Fig. 7 and
Supporting Information), supporting the hypothesis that
kinase inhibitors that bind at such sites may have advantages
over the type I and type II inhibitor classes (Mu¨ller et al.,
2015).
4. Conclusions
The X-ray crystal structures of five ERK5 inhibitors bound to
the kinase domain of ERK5 revealed two different binding
modes. The conventional, so-called type I, kinase inhibitor-
binding mode is demonstrated by structures of ERK5 co-
crystallized with the aminopyrimidine-containing compounds
2 and 3, while a novel allosteric binding mode was observed
for three triazole-containing compounds (compounds 4–6).
The most potent allosteric inhibitor, compound 5, has an IC50
of 2.3 mM in an assay of ERK5 kinase activity, compared with
an IC50 of 42 nM for the conventional kinase inhibitor 3. The
allosteric binding site is a cryptic site that is absent from other
structures of ERK5 and is located between the P-loop and the
C helix. As a consequence of the binding of compounds 4–6,
the P-loop is pushed away from the C helix towards the ATP-
binding site, suggesting that these allosteric inhibitors will also
be ATP-competitive. An ATP-competition study confirmed
this hypothesis. Kinase-selectivity screening showed compound
5 to be more selective than the type I inhibitors 2 and 3, with
significant activity against only five kinases out of the 225
tested. This novel ERK5 allosteric binding mode may provide
a new route to the design of selective ERK5 inhibitors as
therapeutic agents.
Acknowledgements
We are grateful to our AstraZeneca colleagues Ian Sinclair,
Loredana Spadola, Qingbei Zeng, Yue Shao and Wei Zhong,
external consultant Neil Hales and placement student Thomas
Siu for their input and valuable discussion. Part of this
research was undertaken on the MX2 beamline at the
Australian Synchrotron, Victoria, Australia. The authors
would also like to thank Diamond Light Source, the European
Synchrotron Radiation Facility (ESRF) and the Swiss Light
Source (SLS) for beamtime and the staff of beamlines I02,
ID23.1 and X06SA, respectively, for assistance with crystal
testing and data collection.
References
Abe, J., Kusuhara, M., Ulevitch, R. J., Berk, B. C. & Lee, J.-D. (1996).
J. Biol. Chem. 271, 16586–16590.
Afonine, P. V., Grosse-Kunstleve, R. W., Echols, N., Headd, J. J.,
Moriarty, N. W., Mustyakimov, M., Terwilliger, T. C., Urzhumtsev,
A., Zwart, P. H. & Adams, P. D. (2012). Acta Cryst. D68, 352–367.
Betzi, S., Alam, R., Martin, M., Lubbers, D. J., Han, H., Jakkaraj, S. R.,
Georg, G. I. & Schonbrunn, E. (2011). ACS Chem. Biol. 6, 492–501.
Bricogne, G., Blanc, E., Brandl, M., Flensburg, C., Keller, P., Paciorek,
W., Roversi, P., Sharff, A., Smart, O. S., Vonrhein, C. & Womack,
T. O. (2011). BUSTER v.1.11.5. Global Phasing Ltd, Cambridge,
England.
Bruno, I. J., Cole, J. C., Kessler, M., Luo, J., Motherwell, W. D. S.,
Purkis, L. H., Smith, B. R., Taylor, R., Cooper, R. I., Harris, S. E. &
Orpen, A. G. (2004). J. Chem. Inf. Model. 44, 2133–2144.
Chaikuad, A., Tacconi, E. M., Zimmer, J., Liang, Y., Gray, N. S.,
Tarsounas, M. & Knapp, S. (2014). Nature Chem. Biol. 10, 853–860.
Chang, L. & Karin, M. (2001). Nature (London), 410, 37–40.
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino,
R. M., Kapral, G. J., Murray, L. W., Richardson, J. S. & Richardson,
D. C. (2010). Acta Cryst. D66, 12–21.
Deng, X. et al. (2013). Eur. J. Med. Chem. 70, 758–767.
research papers
692 Chen et al.  Novel allosteric inhibitor-binding site in ERK5 Acta Cryst. (2016). D72, 682–693
electronic reprint
Dinev, D., Jordan, B. W. M., Neufeld, B., Lee, J.-D., Lindemann, D.,
Rapp, U. R. & Ludwig, S. (2001). EMBO Rep. 2, 829–834.
Elkins, J. M., Wang, J., Deng, X., Pattison, M. J., Arthur, J. S., Erazo,
T., Gomez, N., Lizcano, J. M., Gray, N. S. & Knapp, S. (2013). J.
Med. Chem. 56, 4413–4421.
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. (2010). Acta
Cryst. D66, 486–501.
Esparı´s-Ogando, A., Dı´az-Rodrı´guez, E., Montero, J. C., Yuste, L.,
Crespo, P. & Pandiella, A. (2002). Mol. Cell. Biol. 22, 270–285.
Evans, P. R. & Murshudov, G. N. (2013). Acta Cryst. D69, 1204–1214.
Garaude, J., Cherni, S., Kaminski, S., Delepine, E., Chable-Bessia, C.,
Benkirane, M., Borges, J., Pandiella, A., In˜iguez, M. A., Fresno, M.,
Hipskind, R. A. & Villalba, M. (2006). J. Immunol. 177, 7607–
7617.
Gavine, P. R. et al. (2015). BMC Cancer, 15, 454.
Guimara˜es, C. R. W., Rai, B. K., Munchhof, M. J., Liu, S., Wang, J.,
Bhattacharya, S. K. & Buckbinder, L. (2011). J. Chem. Inf. Model.
51, 1199–1204.
Han, S. et al. (2014). Biochem. J. 460, 211–222.
Hatzivassiliou, G. et al. (2013). Nature (London), 501, 232–236.
Hayashi, M., Kim, S.-W., Imanaka-Yoshida, K., Yoshida, T., Abel,
E. D., Eliceiri, B., Yang, Y., Ulevitch, R. J. & Lee, J.-D. (2004). J.
Clin. Invest. 113, 1138–1148.
Kabsch, W. (2010). Acta Cryst. D66, 125–132.
Kamakura, S., Moriguchi, T. & Nishida, E. (1999). J. Biol. Chem. 274,
26563–26571.
Knight, Z. A. & Shokat, K. M. (2005). Chem. Biol. 12, 621–637.
Laskowski, R. A., MacArthur, M. W., Moss, D. S. & Thornton, J. M.
(1993). J. Appl. Cryst. 26, 283–291.
Lee, J.-D., Ulevitch, R. J. & Han, J. (1995). Biochem. Biophys. Res.
Commun. 213, 715–724.
Martin, M. P., Alam, R., Betzi, S., Ingles, D. J., Zhu, J.-Y. &
Scho¨nbrunn, E. (2012). Chembiochem, 13, 2128–2136.
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D.,
Storoni, L. C. & Read, R. J. (2007). J. Appl. Cryst. 40, 658–674.
McNicholas, S., Potterton, E., Wilson, K. S. & Noble, M. E. M. (2011).
Acta Cryst. D67, 386–394.
McPhillips, T. M., McPhillips, S. E., Chiu, H.-J., Cohen, A. E., Deacon,
A. M., Ellis, P. J., Garman, E., Gonzalez, A., Sauter, N. K.,
Phizackerley, R. P., Soltis, S. M. & Kuhn, P. (2002). J. Synchrotron
Rad. 9, 401–406.
Mehta, P. B., Jenkins, B. L., McCarthy, L., Thilak, L., Robson, C. N.,
Neal, D. E. & Leung, H. Y. (2003). Oncogene, 22, 1381–1389.
Montero, J. C., Ocan˜a, A., Abad, M., Ortiz-Ruiz, M. J., Pandiella, A.
& Esparı´s-Ogando, A. (2009). PLoS One, 4, e5565.
Mu¨ller, S., Chaikuad, A., Gray, N. S. & Knapp, S. (2015). Nature
Chem. Biol. 11, 818–821.
Ohren, J. F. et al. (2004). Nature Struct. Mol. Biol. 11, 1192–
1197.
Pearson, G., Robinson, F., Beers Gibson, T., Xu, B., Karandikar, M.,
Berman, K. & Cobb, M. H. (2001). Endocr. Rev. 22, 153–183.
Raman, M., Chen, W. & Cobb, M. H. (2007). Oncogene, 26, 3100–
3112.
Regan, C. P., Li, W., Boucher, D. M., Spatz, S., Su, M. S. & Kuida, K.
(2002). Proc. Natl Acad. Sci. USA, 99, 9248–9253.
Rovida, E., Spinelli, E., Sdelci, S., Barbetti, V., Morandi, A., Giuntoli,
S. & Dello Sbarba, P. (2008). J. Immunol. 180, 4166–4172.
Sharff, A., Keller, P., Vonrhein, C., Smart, O. S., Womack, T. O.,
Flensburg, C., Paciorek, W. & Bricogne, G. (2011). Pipedream,
v.0.1.5. Global Phasing Ltd, Cambridge, England.
Smart, O. S., Womack, T. O., Sharff, A., Flensburg, C., Keller, P.,
Paciorek, W., Vonrhein, C. & Bricogne, G. (2011). Grade, v.1.2.3.
Global Phasing Ltd, Cambridge, England.
Sohn, S. J., Lewis, G. M. & Winoto, A. (2008). EMBO J. 27, 1896–
1906.
Song, H., Jin, X. & Lin, J. (2004). Oncogene, 23, 8301–8309.
Tatake, R. J., O’Neill, M. M., Kennedy, C. A., Wayne, A. L., Jakes, S.,
Wu, D., Kugler, S. Z. Jr, Kashem, M. A., Kaplita, P. & Snow, R. J.
(2008). Biochem. Biophys. Res. Commun. 377, 120–125.
Templeton, I. E. & Musib, L. (2015). Curr. Opin. Pharmacol. 23,
61–67.
Wang, X., Merritt, A. J., Seyfried, J., Guo, C., Papadakis, E. S.,
Finegan, K. G., Kayahara, M., Dixon, J., Boot-Handford, R. P.,
Cartwright, E. J., Mayer, U. & Tournier, C. (2005). Mol. Cell. Biol.
25, 336–345.
Weldon, C. B., Scandurro, A. B., Rolfe, K. W., Clayton, J. L., Elliott, S.,
Butler, N. N., Melnik, L. I., Alam, J., McLachlan, J. A., Jaffe, B. M.,
Beckman, B. S. & Burow, M. E. (2002). Surgery, 132, 293–301.
Winn, M. D. et al. (2011). Acta Cryst. D67, 235–242.
Womack, T. O., Smart, O. S., Sharff, A., Flensburg, C., Keller, P.,
Paciorek, W., Vonrhein, C. & Bricogne, G. (2010). Rhofit v.1.2.3.
Global Phasing Ltd, Cambridge, England.
Yang, Q., Deng, X., Lu, B., Cameron, M., Fearns, C., Patricelli, M. P.,
Yates, J. R., Gray, N. S. & Lee, J.-D. (2010). Cancer Cell, 18,
258–267.
Zen, K. et al. (2009). Cancer, 48, 109–120.
Zhang, J., Yang, P. L. & Gray, N. S. (2009). Nature Rev. Cancer, 9,
28–39.
Zhou, G., Bao, Z. Q. & Dixon, J. E. (1995). J. Biol. Chem. 270, 12665–
12669.
research papers
Acta Cryst. (2016). D72, 682–693 Chen et al.  Novel allosteric inhibitor-binding site in ERK5 693
electronic reprint
